FBLG NASDAQ
FibroBiologics, Inc. Common Stock
1W: +1.3%
1M: -31.5%
3M: +42.3%
YTD: -80.6%
1Y: -89.3%
$0.93
-0.01 (-0.87%)
Weekly Expected Move ±10.0%
$1
$1
$1
$1
$1
Credit Risk of going bust: higher than 92% of companies Debt: 19.1% of company value Bonds: none of note held by US funds details ▾
If the stock fell to about $0.05 (down 95%), FibroBiologics, Inc. Common Stock would be worth roughly what it owes.
Total debt $1.5M against a stock market value of $6.2M.
Distance to default 1.22 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $664K (short-term plus half of long-term), stock volatility 139.1%; Altman Z'' -36.66. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Total debt $1.5M against a stock market value of $6.2M.
Distance to default 1.22 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $664K (short-term plus half of long-term), stock volatility 139.1%; Altman Z'' -36.66. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Moderate
50
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$6.2M
52W Range0.62-9.6
Volume26,590
Avg Volume196,471
Beta1.22
Dividend—
Analyst Ratings
Company Info
CEOPeter O'Heeron
Employees15
SectorHealthcare
IndustryBiotechnology
IPO Date2024-02-01
Websitefibrobiologics.com
455 East Medical Center Boulevard
Houston, TX 77598
US
Houston, TX 77598
US
281 651 5150
About FibroBiologics, Inc. Common Stock
FibroBiologics, Inc. operates as a clinical-stage biopharmaceutical firm, advancing therapies derived from fibroblasts toward commercialization within the United States. The company's pipeline includes CybroCell, currently being developed to address degenerative disc disease; CYMS101, targeting multiple sclerosis; and CYWC628 for wound repair. Further demonstrating its broad scope, early-stage investigations are underway for CYTER915, aimed at restoring or enhancing thymus and/or spleen function; CYPS317, for psoriasis; and TCB190, designed to combat specific cancers. FibroBiologics was founded in 2021 and is situated in Houston, Texas.
Latest News
FibroBiologics Advances Patient Dosing for Phase 1/2 Clinical Trial of CYWC628 for the Treatment of Diabetic Foot Ulcers
12 Health Care Stocks Moving In Wednesday's After-Market Session
EXCLUSIVE: FibroBiologics Doses First Patients In Diabetic Foot Ulcers Clinical Trial
FibroBiologics Files Patent Application for Oral Administration of Fibroblast Therapeutics
FibroBiologics Advancing Development of a Fibroblast Treatment for Hantavirus
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Khoja Hamid | A-Award | 298,508 | $1.68 | 2026-09-15 |
| Khoja Hamid | A-Award | 298,508 | $1.55 | 2026-09-15 |
| Steinberg Leigh | 0 | — | 2026-08-20 | |
| Niklas Victoria Nino | A-Award | 30,803 | $0.75 | 2026-06-23 |
| Hoffman Robert E. | A-Award | 30,803 | $0.75 | 2026-06-23 |